Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAPTIST study of baricitinib in calcium pyrophosphate deposition disease
2024-511864-95-00Phase 2Authorised
- Sponsor
- IRCCS Ospedale Galeazzi-Sant'Ambrogio
- Start
- Sep 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of baricitinib, methotrexate, hydroxychloroquine, colchicine and methylprednisolone in chondrocalcinosis (CPPD) (2 arms), sponsored by IRCCS Ospedale Galeazzi-Sant'Ambrogio. Primary endpoint: Change from baseline in CD68 at 12 weeks. Planned start Sep 2024; status: authorised.
02
Drugs
baricitinibmethotrexatehydroxychloroquinecolchicinemethylprednisolone
03
Conditions
chondrocalcinosis (CPPD)
Beyond the preview
Go deeper on 2024-511864-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511864-95-00.